Total Liabilities Summary of Virbac SA

Virbac SA's latest annual total liabilities in 2023 was 566.67 Million EUR , up 14.59% from previous year.
Virbac SA's latest quarterly total liabilities in 2024 Q1 was 801.99 Million EUR , up 41.53% from previous quarter.
Virbac SA reported annual total liabilities of 494.52 Million EUR in 2022, up 3.81% from previous year.
Virbac SA reported annual total liabilities of 476.36 Million EUR in 2021, up 4.86% from previous year.
Virbac SA reported quarterly total liabilities of 801.99 Million EUR for 2024 Q2, down 0.0% from previous quarter.
Virbac SA reported quarterly total liabilities of 522.7 Million EUR for 2023 Q1, up 5.7% from previous quarter.

Annual Total Liabilities Chart of Virbac SA (2023 - 2002)

Historical Annual Total Liabilities of Virbac SA (2023 - 2002)

Year	Total Liabilities	Total Liabilities Growth
2023	566.67 Million EUR	14.59%
2022	494.52 Million EUR	3.81%
2021	476.36 Million EUR	4.86%
2020	454.28 Million EUR	-41.11%
2019	771.38 Million EUR	-0.71%
2018	776.93 Million EUR	-2.7%
2017	798.48 Million EUR	-10.92%
2016	896.37 Million EUR	-5.47%
2015	948.26 Million EUR	12.34%
2014	844.06 Million EUR	75.17%
2013	481.85 Million EUR	12.25%
2012	429.28 Million EUR	56.23%
2011	274.76 Million EUR	18.74%
2010	231.39 Million EUR	16.71%
2009	198.27 Million EUR	-6.32%
2008	211.64 Million EUR	10.03%
2007	192.35 Million EUR	-10.09%
2006	213.93 Million EUR	38.8%
2005	154.13 Million EUR	-5.42%
2004	162.96 Million EUR	1240.56%
2003	-14.28 Million EUR	-102.81%
2002	-7.04 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	801.99 Million EUR	41.53%
2024 Q2	801.99 Million EUR	0.0%
2023 Q1	522.7 Million EUR	5.7%
2023 Q4	566.67 Million EUR	3.82%
2023 Q3	545.81 Million EUR	4.42%
2023 Q2	522.7 Million EUR	0.0%
2023 FY	566.67 Million EUR	14.59%
2022 Q4	494.52 Million EUR	0.04%
2022 Q1	511.88 Million EUR	7.46%
2022 FY	494.52 Million EUR	3.81%
2022 Q2	511.88 Million EUR	0.0%
2022 Q3	494.33 Million EUR	-3.43%
2021 FY	476.36 Million EUR	4.86%
2021 Q1	462.67 Million EUR	1.85%
2021 Q3	476.36 Million EUR	2.96%
2021 Q4	476.36 Million EUR	0.0%
2021 Q2	462.67 Million EUR	0.0%
2020 FY	454.28 Million EUR	-41.11%
2020 Q2	759.24 Million EUR	0.0%
2020 Q4	454.28 Million EUR	-0.0%
2020 Q1	759.24 Million EUR	-1.57%
2020 Q3	454.28 Million EUR	-40.17%
2019 Q4	771.38 Million EUR	0.0%
2019 Q2	799.8 Million EUR	0.0%
2019 Q3	771.38 Million EUR	-3.55%
2019 Q1	799.8 Million EUR	2.94%
2019 FY	771.38 Million EUR	-0.71%
2018 Q3	776.93 Million EUR	-5.0%
2018 Q1	817.83 Million EUR	2.42%
2018 FY	776.93 Million EUR	-2.7%
2018 Q4	776.93 Million EUR	0.0%
2018 Q2	817.83 Million EUR	0.0%
2017 Q4	798.48 Million EUR	0.0%
2017 FY	798.48 Million EUR	-10.92%
2017 Q2	858.18 Million EUR	0.0%
2017 Q1	858.18 Million EUR	-4.26%
2017 Q3	798.48 Million EUR	-6.96%
2016 Q1	931.83 Million EUR	-1.73%
2016 FY	896.37 Million EUR	-5.47%
2016 Q4	896.37 Million EUR	0.0%
2016 Q3	896.37 Million EUR	-3.81%
2016 Q2	931.83 Million EUR	0.0%
2015 FY	948.26 Million EUR	12.34%
2015 Q4	948.26 Million EUR	0.0%
2015 Q1	940.9 Million EUR	11.47%
2015 Q3	948.26 Million EUR	0.78%
2015 Q2	940.9 Million EUR	0.0%
2014 Q3	843.65 Million EUR	57.76%
2014 Q1	534.77 Million EUR	10.98%
2014 FY	844.06 Million EUR	75.17%
2014 Q4	844.06 Million EUR	0.05%
2014 Q2	534.77 Million EUR	0.0%
2013 FY	481.85 Million EUR	12.25%
2013 Q4	481.85 Million EUR	0.0%
2013 Q3	481.85 Million EUR	5.19%
2013 Q2	458.08 Million EUR	0.0%
2013 Q1	458.08 Million EUR	6.71%
2012 FY	429.28 Million EUR	56.23%
2012 Q4	429.28 Million EUR	0.0%
2012 Q2	311 Million EUR	0.0%
2011 Q2	254.06 Million EUR	0.0%
2011 Q4	274.76 Million EUR	0.0%
2011 FY	274.76 Million EUR	18.74%
2010 FY	231.39 Million EUR	16.71%
2010 Q2	240.29 Million EUR	0.0%
2010 Q4	231.39 Million EUR	0.0%
2009 Q4	198.27 Million EUR	0.0%
2009 FY	198.27 Million EUR	-6.32%
2008 FY	211.64 Million EUR	10.03%
2007 FY	192.35 Million EUR	-10.09%
2006 FY	213.93 Million EUR	38.8%
2005 FY	154.13 Million EUR	-5.42%
2004 FY	162.96 Million EUR	1240.56%
2003 FY	-14.28 Million EUR	-102.81%
2002 FY	-7.04 Million EUR	0.0%

Peer Total Liabilities Comparison of Virbac SA

Name	Total Liabilities	Total Liabilities Difference
AstraZeneca PLC	61.86 Billion USD	99.084%
Bristol-Myers Squibb Company PFD CONV 2	65.67 Billion USD	99.137%
CSPC Pharmaceutical Group Limited	1.53 Billion USD	63.198%
Clarus Therapeutics Holdings, Inc.	67.62 Million USD	-737.945%
Novartis AG	53.19 Billion USD	98.935%
PT Kalbe Farma Tbk.	255.94 Million USD	-121.41%

Global Stocks Search

Virbac SA (VRBCF)

Total Liabilities Summary of Virbac SA

Annual Total Liabilities Chart of Virbac SA (2023 - 2002)

Historical Annual Total Liabilities of Virbac SA (2023 - 2002)

Peer Total Liabilities Comparison of Virbac SA